KU-32

Research use only, not for human use.

A novel, novobiocin-based, C-terminal inhibitor of Hsp90 and a potent inducer of Hsp70.

A novel, novobiocin-based, C-terminal inhibitor of Hsp90 and a potent inducer of Hsp70; protects against neuronal death induced by amyloid β-peptide with minimally cytotoxic to primary cortical neurons; significantly increases the expression of Hsp70 in MCF7 cells at 10 nM, decreases neurodegeneration of non-myelinated or myelinated sensory neurons in vitro and attenuates the pathophysiological progression of DPN in mice.

Treating human islets with KU-32 for 24 hours shows no toxicity. With a minimum of 2-day exposure, KU-32 improves cellular viability by blocking apoptosis. Functionally, isolated human islets release more glucose-stimulated insulin when preincubate in KU-32. KU-32 protects against glucose-induced death of embryonic DRG (dorsal root ganglia) neurons cultured for 3 days in vitro.

Diabetic BKS-db/db mice, a model for type 2 diabetes, administered KU-32 for 10 weeks do not show any significant changes in blood glucose and insulin levels, despite having greater insulin staining/beta cell in the pancreas compared to untreated BKS db/db mice.

KU 32 | KU32

Cytoskeleton/Cell Adhesion Molecules

HSP

HSP

——

——

956498-70-7

407.419

C20H25NO8

>98% (HPLC)

——

CC(NC(C1=O)=CC2=C(O1)C(C)=C(O[C@H]3[C@H](O)[C@H](O)[C@@H](OC)C(C)(C)O3)C=C2)=O

N-{7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy]-8-methyl-2-oxo-2H-chromen-3-yl}acetamide

(-20℃)

With Ice Pack

≥ 2 years